Common variations in CYP2C9 and VKORC1 that affect warfarin dose.
| . | . | . | Prevalence, % . | |||
|---|---|---|---|---|---|---|
| . | Name . | Variation . | Caucasian . | African . | Asian . | Effect on warfarin dose, % . |
| † Data approximate from references 13,14,16,17 | ||||||
| ‡ From reference 12 | ||||||
| §From references 12,14 | ||||||
| CYP2C9 | ||||||
| *1 | Wild-type | 81 | 94 | 98 | Reference | |
| *2 | R144C | 13 | 3 | 0 | − 20† | |
| *3 | I359L | 7 | 2 | 2 | − 30† | |
| VKORC1 | ||||||
| Group A | Haplotypes 1,2‡ | 37 | 14 | 89 | −20§ | |
| Group B | Haplotypes 7,8,9 | 58 | 49 | 10 | Reference | |
| . | . | . | Prevalence, % . | |||
|---|---|---|---|---|---|---|
| . | Name . | Variation . | Caucasian . | African . | Asian . | Effect on warfarin dose, % . |
| † Data approximate from references 13,14,16,17 | ||||||
| ‡ From reference 12 | ||||||
| §From references 12,14 | ||||||
| CYP2C9 | ||||||
| *1 | Wild-type | 81 | 94 | 98 | Reference | |
| *2 | R144C | 13 | 3 | 0 | − 20† | |
| *3 | I359L | 7 | 2 | 2 | − 30† | |
| VKORC1 | ||||||
| Group A | Haplotypes 1,2‡ | 37 | 14 | 89 | −20§ | |
| Group B | Haplotypes 7,8,9 | 58 | 49 | 10 | Reference | |